Prostate Care Articles & Analysis
16 news found
“We are committed to improving prostate cancer care across all stages of the disease and recognize that for patients and their families, quality of life is just as critical as prolonging survival and delaying disease progression. ...
ByBayer AG
“An important part of our mission at Bayer is to transform prostate cancer care and improve patient outcomes at various stages of the disease. ...
ByBayer AG
Nubeqa™ (darolutamide), which has the potential to become the standard of care for prostate cancer patients from the early- to the late-stage of this disease, has projected peak sales potential of more than three billion euros. Its market share in the US has already expanded to over 30 percent in non-metastatic castration-resistant prostate ...
ByBayer AG
Because of this funding, we are leading international trials in recruitment and conducting important clinical trials locally to help improve the quality of prostate cancer care for Albertans,” shares Dr. Kinnaird. During his ten-year tenure as the Frank and Carla Sojonky Chair, Dr. ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version 1.2022). ...
F-rhPSMA-7.3 is an investigational Prostate-Specific Membrane Antigen-targeted radiohybrid (rh) PET imaging agent. ...
“We expect that IsoPSA, our novel blood-based prostate cancer test, may fundamentally shift the diagnostic paradigm of prostate cancer, and improve patient care and ...
Basel, September 17, 2021 — Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant prostate cancer (mCRPC) versus standard of care alone. ...
Klein provided data used to validate the diagnostic accuracy of the novel, structure-based IsoPSA assay to improve early detection strategies for prostate cancer vs. standard of care PSA and % free PSA tests. In the prospective, multicenter study of 1,093 men IsoPSA showed an AUC of 0.790 for the detection of high grade cancer (Gleason grade group 2 or higher) ...
“We believe that Akumin will be a particularly strong partner for us given its strategy to become a leading full-service provider of men’s health and its geographic density in Florida, one of the largest markets for prostate care in the country,” commented Arun Menawat, Profound’s CEO and Chairman. ...
The Annual Prostate Cancer Awareness Day (PCAD) at the Massachusetts State House was established in September 2009 by the AdMeTech Foundation, a non-profit organization. ...
The ExoDx™ Prostate (EPI) test played an important role in the management of Cal's prostate cancer. One in nine American men will be diagnosed with prostate cancer during their lifetime. Prostate cancer (PCa) is the second leading cause of cancer death among American men and is the most commonly diagnosed cancer. ...
In honor of November being prostate cancer awareness month, today’s post is dedicated to discussing prostate exams and how medical professionals can help make them as comfortable as possible. This is in an effort to help promote as many men as possible to have their prostates checked to reduce the incidence of prostate cancer or to identify it in the earlier stages. Before we dive right ...
” Cleveland Diagnostics has concluded two multicenter clinical trials in top U.S. and international hospitals and clinics, led by Cleveland Clinic, in which the diagnostic accuracy of IsoPSA was compared to that of PSA, the current standard of care in prostate cancer, in men scheduled for prostate biopsy. The results from those studies ...
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced the online publication of results from a multicenter validation study of IsoPSA™, a novel structure-based prostate cancer assay, in Journal of Urology. The study validated the findings from a preliminary study published ...
Dako, an Agilent Technologies company and worldwide provider of cancer diagnostics, today announced the release of a new review paper titled "Immunohistochemistry in Prostate Pathology" that illustrates the significant impact immunohistochemistry (IHC) can have on diagnostic prostate pathology. ...